VTE, thrombophilia, antithrombotic therapy, and pregnancy - Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines

Chest

Volumn 141, Issue 2 SUPPL., 2012, Pages e691S-e736S

  Bates, Shannon M ^a   Greer, A ^b   Middeldorp, Saskia ^c   Veenstra, David L ^d   Prabulos, Anne Marie ^e   Vandvik, Per Olav ^f  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF WASHINGTON   (United States)

^e UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^f INNLANDET HOSPITAL TRUST   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING FACTOR 5 LEIDEN; COUMARIN; DABIGATRAN; DALTEPARIN; DANAPAROID; ENOXAPARIN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PLACEBO; RECOMBINANT HIRUDIN; REVIPARIN; RIVAROXABAN; THROMBIN INHIBITOR; TINZAPARIN; WARFARIN;

ANTEPARTUM HEMORRHAGE; ANTICOAGULANT THERAPY; ANTICOAGULATION; ANTIPHOSPHOLIPID SYNDROME; BLEEDING; BLOOD CLOT LYSIS; BONE DENSITY; BRACHYDACTYLY; BRAIN HEMORRHAGE; BREAST FEEDING; CENTRAL NERVOUS SYSTEM MALFORMATION; CEREBELLUM ATROPHY; CESAREAN SECTION; CLEFT LIP; CLEFT PALATE; CONGENITAL MALFORMATION; CONTINUOUS INFUSION; CORNEA DISEASE; CORPUS CALLOSUM AGENESIS; DANDY WALKER SYNDROME; DEEP VEIN THROMBOSIS; DEVELOPMENTAL DISORDER; DNA POLYMORPHISM; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; EMBRYO TRANSFER; EMBRYOPATHY; EPIPHYSIOLYSIS; EPISTAXIS; FAMILY HISTORY; FETAL HEMORRHAGE; FETUS DEATH; FETUS WASTAGE; FIBRIN DEPOSITION; FINGER MALFORMATION; GASTROINTESTINAL HEMORRHAGE; GASTROSCHISIS; GENE MUTATION; HEART DISEASE; HEART INFARCTION; HEART VALVE PROSTHESIS; HEMATOMA; HEPARIN INDUCED THROMBOCYTOPENIA; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HYDROCEPHALUS; HYPOPLASIA; INJECTION SITE CONTUSION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE RASH; INTERMITTENT PNEUMATIC COMPRESSION DEVICE; INTERNATIONAL NORMALIZED RATIO; INTRAUTERINE GROWTH RETARDATION; LOW DRUG DOSE; LUNG EMBOLISM; LUNG HEMORRHAGE; MENTAL DEFICIENCY; METABOLIC ACIDOSIS; NONHUMAN; OBSERVATIONAL STUDY; OOCYTE RETRIEVAL; OPTIC NERVE ATROPHY; OSTEOPOROSIS; OVARY HYPERSTIMULATION; PARTIAL THROMBOPLASTIN TIME; PATENT DUCTUS ARTERIOSUS; PLACENTA PREVIA; POLYDACTYLY; POSTHUMOUS CONCEPTION; POSTPARTUM HEMORRHAGE; PRACTICE GUIDELINE; PREECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATION; PREGNANCY DISORDER; PREGNANCY OUTCOME; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; PROSTHETIC VALVE THROMBOSIS; PROTEIN C DEFICIENCY; PUERPERIUM; RECURRENT DISEASE; REVIEW; REYE SYNDROME; RISK FACTOR; SIDE EFFECT; SKIN ALLERGY; SKIN NECROSIS; SOLITARY KIDNEY; SOLUTIO PLACENTAE; SPONTANEOUS ABORTION; STRABISMUS; TERATOGENICITY; THROMBOCYTE DYSFUNCTION; THROMBOEMBOLISM; THROMBOPHILIA; THROMBOSIS PREVENTION; TOE MALFORMATION; TREATMENT DURATION; VAGINA BLEEDING; VASCULITIS; VENOUS THROMBOEMBOLISM; VERTEBRA FRACTURE;

EID: 84856809942     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.11-2300     Document Type: Article

References (343)

1. Schulman S, Kearon C;Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692-694.
2. Guyatt GH, Oxman AD, Vist GE, et al GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924-926.
3. Guyatt G, Gutterman D, Baumann MH, et al. Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians task force. Chest. 2006;129(1):174-181.
4. Guyatt GH, Norris SL, Schulman S, et al. Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2)(suppl):53S-70S.
5. MacLean S, Mulla S, Akl E, et al. Patient values and preferences in decision making for antithrombotic therapy: a systematic review: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2)(suppl):e1S-e23S.
6. Chunilal SD, Young E, Johnston MA, et al. The APTT response of pregnant plasma to unfractionated heparin. Thromb Haemost. 2002;87(1):92-97.
7. Ginsberg JS, Kowalchuk G, Hirsh J, Brill-Edwards P, Burrows R. Heparin therapy during pregnancy. Risks to the fetus and mother. Arch Intern Med. 1989;149(10):2233-2236.
8. Hull RD, Delmore TJ, Carter CJ, et al. Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. N Engl J Med. 1982; 306(4):189-194.
9. Hull RD, Hirsh J, Jay R, et al. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med. 1982;307(27):1676-1681.
10. Kearon C, Ginsberg JS, Kovacs MJ, et al Extended Low-Intensity Anticoagulation for Thrombo-Embolism Investigators. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med.2003;349(7):631- 639.
11. Anderson DR, Ginsberg JS, Burrows R, Brill-Edwards P. Subcutaneous heparin therapy during pregnancy: a need for concern at the time of delivery. Thromb Haemost. 1991;65(3):248-250.
12. Burrows RF, Kelton JG. Incidentally detected thrombocytopenia in healthy mothers and their infants. N Engl J Med. 1988;319(3):142-145.
13. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular weight heparin or unfractionated heparin. N Engl J Med.1995;332(20):1330-1335.
14. Linkins L-A, Dans AL, Moores LK, et al. Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 141(2)(suppl):e495S-e530S.
15. de Valk HW, Banga JD, Wester JWJ, et al. Comparing subcutaneous danaparoid with intravenous unfractionated heparin for the treatment of venous thromboembolism. A randomized controlled trial. Ann Intern Med. 1995;123(1):1-9.
16. Peeters LLH, Hobbelen PMJ, Verkeste CM, et al. Placental transfer of Org 10172, a low-molecular weight heparinoid, in the awake late-pregnant guinea pig. Thromb Res. 1986;44(3):277-283.
17. Henny CP, ten Cate H, ten Cate JW, Prummel MF, Peters M, Büller HR. Thrombosis prophylaxis in an AT III deficient pregnant woman: application of a low molecular weight heparinoid. Thromb Haemost. 1986;55(2):301.
18. Greinacher A, Eckhardt T, Mussmann J, Mueller-Eckhardt C. Pregnancy complicated by heparin associated thrombocytopenia: management by a prospectively in vitro selected heparinoid (Org 10172). Thromb Res. 1993;71(2):123-126.
19. Magnani HN. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172). Thromb Haemost. 1993;70(4):554-561.
20. Rubin N, Rubin J. Treatment of heparin induced thrombocytopenia with thrombosis (HITT) in pregnancy with fondaparinux [abstract]. Paper presented at: the 45th Annual Meeting of the American Society of Hematology; December 6-9, 2003;San Diego, CA.
21. Parody R, Oliver A, Souto JC, Fontcuberta J. Fondaparinux (ARIXTRA) as an alternative anti-thrombotic prophylaxis when there is hypersensitivity to low molecular weight and unfractionated heparins. Haematologica. 2003;88(11):ECR32.
22. Douketis JD, Ginsberg JS, Burrows RF, Duku EK, Webber CE, Brill-Edwards P. The effects of long-term heparin therapy during pregnancy on bone density. A prospective matched cohort study. Thromb Haemost. 1996;75(2):254-257.
23. Dahlman TC. Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin. Am J Obstet Gynecol. 1993;168(4):1265-1270.
24. Ginsberg JS, Kowalchuk G, Hirsh J, et al. Heparin effect on bone density. Thromb Haemost. 1990;64(2):286-289.
25. Dahlman TC, Lindvall N, Hellgren M. Osteopenia in pregnancy during long-term heparin treatment: a radiological study post partum. Br J Obstet Gynaecol. 1990;97(3):221-228.
26. Monreal M, Lafoz E, Olive A, del Rio L, Vedia C. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thromb Haemost. 1994;71(1):7-11.
27. Pettilä V, Leinonen P, Markkola A, Hiilesmaa V, Kaaja R. Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. Thromb Haemost. 2002;87(2):182-186.
28. Muir JM, Andrew M, Hirsh J, et al. Histomorphometric analysis of the effects of standard heparin on trabecular bone in vivo. Blood. 1996;88(4):1314-1320.
29. Muir JM, Hirsh J, Weitz JI, Andrew M, Young E, Shaughnessy SG. A histomorphometric comparison of the effects of heparin and low-molecular-weight heparin on cancellous bone in rats. Blood. 1997;89(9):3236-3242.
30. Shaughnessy SG, Hirsh J, Bhandari M, Muir JM, Young E, Weitz JI. A histomorphometric evaluation of heparininduced bone loss after discontinuation of heparin treatment in rats. Blood. 1999;93(4):1231-1236.
31. Harenberg J, Hoffmann U, Huhle G, Winkler M, Bayerl C. Cutaneous reactions to anticoagulants. Recognition and management. Am J Clin Dermatol. 2001;2(2):69-75.
32. Gould MK, Dembitzer AD, Doyle RL, Hastie TJ, Garber AM. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann Intern Med. 1999;130(10):800-809.
33. Quinlan DJ, McQuillan A, Eikelboom JW. Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized, controlled trials. Ann Intern Med. 2004;140(3):175-183.
34. Eikelboom JW, Anand SS, Malmberg K, Weitz JI, Ginsberg JS, Yusuf S. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet. 2000;355(9219):1936- 1942.
35. Weitz JI. Low-molecular-weight heparins [published correction appears in N Engl J Med. 1997;337(21):1567]. N Engl J Med. 1997;337(10):688-698.
36. Lepercq J, Conard J, Borel-Derlon A, et al. Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies. BJOG. 2001;108(11):1134-1140.
37. Sanson BJ, Lensing AWA, Prins MH, et al. Safety of low-molecular- weight heparin in pregnancy: a systematic review. Thromb Haemost. 1999;81(5):668-672.
38. Greer IA, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood. 2005;106(2):401-407.
39. Carlin AJ, Farquharson RG, Quenby SM, Topping J, Fraser WD. Prospective observational study of bone mineral density during pregnancy: low molecular weight heparin versus control. Hum Reprod. 2004;19(5):1211-1214.
40. Rodger MA, Kahn SR, Cranney A, et al; TIPPS investigators. Long-term dalteparin in pregnancy not associated with a decrease in bone mineral density: substudy of a randomized controlled trial. J Thromb Haemost. 2007; 5(8):1600- 1606.
41. Lefkou E, Khamashta M, Hampson G, Hunt BJ. Review: Low-molecular-weight heparin-induced osteoporosis and osteoporotic fractures: a myth or an existing entity? Lupus. 2010;19(1):3-12.
42. Byrd LM, Shiach CR, Hay CRM, Johnston TA. Osteo penic fractures in pregnancy: is low molecular weight heparin (LMWH) implicated? J Obstet Gynaecol. 2008; 28(5):539- 542.
43. Hunt BJ, Doughty HA, Majumdar G, et al. Thromboprophylaxis with low molecular weight heparin (Fragmin) in high risk pregnancies. Thromb Haemost. 1997;77(1):39-43.
44. Bauersachs RM, Dudenhausen J, Faridi A, et al; EThIG Investigators. Risk stratification and heparin prophylaxis to prevent venous thromboembolism in pregnant women. Thromb Haemost. 2007;98(6):1237-1245.
45. Bank I, Libourel EJ, Middeldorp S, Van Der Meer J, Büller HR. High rate of skin complications due to low-molecular-weight heparins in pregnant women. J Thromb Haemost. 2003;1(4):859-861.
46. Wütschert R, Piletta P, Bounameaux H. Adverse skin reactions to low molecular weight heparins: frequency, management and prevention. Drug Saf. 1999;20(6):515-525.
47. Ginsberg JS, Hirsh J, Turner DC, Levine MN, Burrows R. Risks to the fetus of anticoagulant therapy during pregnancy. Thromb Haemost. 1989;61(2):197-203.
48. Hall JG, Pauli RM, Wilson KM. Maternal and fetal sequelae of anticoagulation during pregnancy. Am J Med. 1980; 68(1):122-140.
49. Chan WS, Anand S, Ginsberg JS. Anticoagulation of pregnant women with mechanical heart valves: a systematic review of the literature. Arch Intern Med. 2000;160(2):191-196.
50. Hassouna A, Allam H. Anticoagulation of pregnant women with mechanical heart valve prosthesis: a systematic review of the literature (2000-2009). J Coagul Disorders. 2010; 2(1):81- 88.
51. Pauli RM, Haun J. Intrauterine effects of coumarin derivatives. Dev Brain Dysfunct. 1993;6:229-247.
52. Ben Ismail M, Abid F, Trabelsi S, Taktak M, Fekih M. Cardiac valve prostheses, anticoagulation, and pregnancy. Br Heart J. 1986;55(1):101-105.
53. Born D, Martinez EE, Almeida PAM, et al. Pregnancy in patients with prosthetic heart valves: the effects of anticoagulation on mother, fetus, and neonate. Am Heart J. 1992;124(2):413-417.
54. Pavankumar P, Venugopal P, Kaul U, et al. Pregnancy in patients with prosthetic cardiac valve. A 10-year experience. Scand J Thorac Cardiovasc Surg. 1988;22(1):19-22.
55. Larrea JL, Núñez L, Reque JA, Gil Aguado M, Matarros R, Minguez JA. Pregnancy and mechanical valve prostheses: a high-risk situation for the mother and the fetus. Ann Thorac Surg. 1983;36(4):459-463.
56. Al-Lawati AAM, Venkitraman M, Al-Delaime T, Valliathu J. Pregnancy and mechanical heart valves replacement; dilemma of anticoagulation. Eur J Cardiothorac Surg. 2002;22(2):223-227.
57. Iturbe-Alessio I, Fonseca MC, Mutchinik O, Santos MA, Zajarías A, Salazar E. Risks of anticoagulant therapy in pregnant women with artificial heart valves. N Engl J Med. 1986;315(22):1390-1393.
58. Schaefer C, Hannemann D, Meister R, et al. Vitamin K antagonists and pregnancy outcome. A multi-centre prospective study. Thromb Haemost. 2006;95(6):949-957.
59. Wesseling J, Van Driel D, Heymans HS, et al. Coumarins during pregnancy: long-term effects on growth and development of school-age children. Thromb Haemost. 2001;85(4):609-613.
60. van Driel D, Wesseling J, Sauer PJJ, van Der Veer E, Touwen BC, Smrkovsky M. In utero exposure to coumarins and cognition at 8 to 14 years old. Pediatrics. 2001;107(1):123-129.
61. Hirsh J, Cade JF, O'Sullivan EF. Clinical experience with anticoagulant therapy during pregnancy. BMJ. 1970;1(5691):270-273.
62. Vitale N, De Feo M, De Santo LS, Pollice A, Tedesco N, Cotrufo M. Dose-dependent fetal complications of warfarin in pregnant women with mechanical heart valves. J Am Coll Cardiol. 1999;33(6):1637-1641.
63. Flessa HC, Kapstrom AB, Glueck HI, Will JJ. Placental transport of heparin. Am J Obstet Gynecol. 1965; 93(4):570- 573.
64. Clark NP, Delate T, Witt DM, Parker S, McDuffie R. A descriptive evaluation of unfractionated heparin use during pregnancy. J Thromb Thrombolysis. 2009;27(3):267-273.
65. Forestier F, Daffos F, Capella-Pavlovsky M. Low molecular weight heparin (PK 10169) does not cross the placenta dur ing the second trimester of pregnancy study by direct fetal blood sampling under ultrasound. Thromb Res. 1984; 34(6):557- 560.
66. Forestier F, Daffos F, Rainaut M, Toulemonde F. Low molecular weight heparin (CY 216) does not cross the placenta during the third trimester of pregnancy. Thromb Haemost. 1987;57(2):234.
67. Lindhoff-Last E, Kreutzenbeck H-J, Magnani HN. Treatment of 51 pregnancies with danaparoid because of heparin intolerance. Thromb Haemost. 2005;93(1):63-69.
68. Lagrange F, Vergnes C, Brun JL, et al. Absence of placental transfer of pentasaccharide (Fondaparinux, Arixtra) in the dually perfused human cotyledon in vitro. Thromb Haemost. 2002;87(5):831-835.
69. Dempfle CE. Minor transplacental passage of fondaparinux in vivo. N Engl J Med. 2004;350(18):1914-1915.
70. Harenberg J. Treatment of a woman with lupus and thromboembolism and cutaneous intolerance to heparins using fondaparinux during pregnancy. Thromb Res. 2007;119(3):385-388.
71. Mazzolai L, Hohlfeld P, Spertini F, Hayoz D, Schapira M, Duchosal MA. Fondaparinux is a safe alternative in case of heparin intolerance during pregnancy. Blood. 2006;108(5):1569-1570.
72. Wijesiriwardana A, Lees DA, Lush C. Fondaparinux as anticoagulant in a pregnant woman with heparin allergy. Blood Coagul Fibrinolysis. 2006;17(2):147-149.
73. Gerhardt A, Zotz RB, Stockschlaeder M, Scharf RE. Fondaparinux is an effective alternative anticoagulant in pregnant women with high risk of venous thromboembolism and intolerance to low-molecular-weight heparins and heparinoids. Thromb Haemost. 2007;97(3):496-497.
74. Schapkaitz E, Jacobson BF. Delayed hypersensitivity to low-molecular-weight heparin (LMWH) in pregnancy. S Afr Med J. 2007;97(12):1255-1257.
75. Winger EE, Reed JL. A retrospective analysis of fondaparinux versus enoxaparin treatment in women with infertility or pregnancy loss. Am J Reprod Immunol. 2009; 62(4):253- 260.
76. Knol HM, Schultinge L, Erwich JJHM, Meijer K. Fondaparinux as an alternative anticoagulant therapy during pregnancy. J Thromb Haemost. 2010;8(8):1876-1879.
77. Lindhoff-Last E, Bauersachs R. Heparin-induced thrombocytopenia- alternative anticoagulation in pregnancy and lactation. Semin Thromb Hemost. 2002;28(5):439-446.
78. Markwardt F, Fink G, Kaiser B, et al. Pharmacological survey of recombinant hirudin. Pharmazie. 1988;43(3)202-207.
79. Mehta R, Golichowski A. Treatment of heparin induced thrombocytopenia and thrombosis during the first trimester of pregnancy. J Thromb Haemost. 2004;2(9):1665-1666.
80. Furlan A, Vianello F, Clementi M, Prandoni P. Heparin-induced thrombocytopenia occurring in the first trimester of pregnancy: successful treatment with lepirudin. A case report. Haematologica. 2006; 91(suppl 8):ECR40.
81. Taniguchi S, Fukuda I, Minakawa M, Watanabe K, Daitoku K, Suzuki Y. Emergency pulmonary embolectomy during the second trimester of pregnancy: report of a case. Surg Today. 2008; 38(1):59-61.
82. Young SK, Al-Mondhiry HA, Vaida SJ, Ambrose A, Botti JJ. Successful use of argatroban during the third trimester of pregnancy: case report and review of the literature. Pharmacotherapy. 2008;28(12):1531-1536.
83. Ekbatani A, Asaro LR, Malinow AM. Anticoagulation with argatroban in a parturient with heparin-induced thrombocytopenia. Int J Obstet Anesth. 2010;19(1):82-87.
84. Boehringer Ingelheim. Summary of product characteristics: dabigatran etexilate. Date of text revision: March 2009
85. Bayer Schering Pharma AG. Summary of product characteristics: rivaroxaban. Date of text revision: May 2009
86. Askie LM, Duley L, Henderson-Smart DJ, Stewart LA; PARIS Collaborative Group. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet. 2007;369(9575):1791-1798.
87. Kozer E, Nikfar S, Costei A, Boskovic R, Nulman I, Koren G. Aspirin consumption during the first trimester of pregnancy and congenital anomalies: a meta-analysis. Am J Obstet Gynecol. 2002;187(6):1623-1630.
88. Kozer E, Costei AM, Boskovic R, Nulman I, Nikfar S, Koren G. Effects of aspirin consumption during pregnancy on pregnancy outcomes: meta-analysis. Birth Defects Res B Dev Reprod Toxicol. 2003;68(1):70-84.
89. Li DK, Liu L, Odouli R. Exposure to non-steroidal antiinfl ammatory drugs during pregnancy and risk of miscarriage: population based cohort study. BMJ. 2003;327(7411):368-372.
90. James AH, Brancazio LR, Price T. Aspirin and reproductive outcomes. Obstet Gynecol Surv. 2008;63(1):49-57.
91. Pfeifer GW. Distribution and placental transfer of 131-I streptokinase. Australas Ann Med. 1970;19(suppl 1):17-18.
92. Leonhardt G, Gaul C, Nietsch HH, Buerke M, Schleussner E. Thrombolytic therapy in pregnancy. J Thromb Thrombolysis. 2006;21(3):271-276.
93. Ahearn GS, Hadjiliadis D, Govert JA, Tapson VF. Massive pulmonary embolism during pregnancy successfully treated with recombinant tissue plasminogen activator: a case report and review of treatment options. Arch Intern Med. 2002;162(11):1221-1227.
94. te Raa GD, Ribbert LSM, Snijder RJ, Biesma DH. Treatment options in massive pulmonary embolism during pregnancy; a case-report and review of literature. Thromb Res. 2009;124(1):1-5.
95. Holden EL, Ranu H, Sheth A, Shannon MS, Madden BP. Thrombolysis for massive pulmonary embolism in pregnancy - a report of three cases and follow up over a two year period. Thromb Res. 2011;127(1):58-59.
96. Berlin CM, Briggs GG. Drugs and chemicals in human milk. Semin Fetal Neonatal Med. 2005;10(2):149-159.
97. Clark SL, Porter TF, West FG. Coumarin derivatives and breast-feeding. Obstet Gynecol. 2000;95(6 Pt 1):938-940.
98. Orme ML, Lewis PJ, de Swiet M, et al. May mothers given warfarin breast-feed their infants? BMJ. 1977;1(6076):1564-1565.
99. McKenna R, Cole ER, Vasan U. Is warfarin sodium contraindicated in the lactating mother? J Pediatr. 1983;103(2):325-327.
100. Houwert-de Jong M, Gerards LJ, Tetteroo-Tempelman CA, de Wolff FA. May mothers taking acenocoumarol breast feed their infants? Eur J Clin Pharmacol. 1981;21(1):61-64.
101. Fondevila CG, Meschengieser S, Blanco A, Peñalva L, Lazzari MA. Effect of acenocoumarine on the breast-fed infant. Thromb Res. 1989;56(1):29-36.
102. O'Reilly R. Anticoagulant, antithrombotic and thrombolytic drugs. In: Gillman AG, Goodman LS, Gillman A, eds. The Pharmacologic Basis of Therapeutics. 6th ed. New York: Macmillan; 1980:1347.
103. Richter C, Sitzmann J, Lang P, Weitzel H, Huch A, Huch R. Excretion of low molecular weight heparin in human milk. Br J Clin Pharmacol. 2001;52(6):708-710.
104. GlaxoSmithKline. Arixtra prescribing information. Date of test revision: January 2010
105. Vetter A, Perera G, Leithner K, Klima G, Bernkop-Schnürch A. Development and in vivo bioavailability study of an oral fondaparinux delivery system. Eur J Pharm Sci. 2010;41(3-4):489-497.
106. Lindhoff-Last E, Willeke A, Thalhammer C, Nowak G, Bauersachs R. Hirudin treatment in a breastfeeding woman. Lancet. 2000;355(9202):467-468.
107. Bar-Oz B, Bulkowstein M, Benyamini L, et al. Use of antibiotic and analgesic drugs during lactation. Drug Saf. 2003;26(13):925-935.
108. Unsworth J, d'Assis-Fonseca A, Beswick DT, Blake DR. Serum salicylate levels in a breast fed infant. Ann Rheum Dis. 1987;46(8):638-639.
109. Needs CJ, Brooks PM. Antirheumatic medication during lactation. Br J Rheumatol. 1985;24(3):291-297.
110. Clark JH, Wilson WG. A 16-day-old breast-fed infant with metabolic acidosis caused by salicylate. Clin Pediatr (Phila). 1981;20(1):53-54.
111. Stuart MJ, Gross SJ, Elrad H, Graeber JE. Effects of acetylsalicylic-acid ingestion on maternal and neonatal hemostasis. N Engl J Med. 1982;307(15):909-912.
112. Louden KA, Broughton Pipkin F, Heptinstall S, et al. Neonatal platelet reactivity and serum thromboxane B2 production in whole blood: the effect of maternal low dose aspirin. Br J Obstet Gynaecol. 1994;101(3):203-208.
113. Ito S, Blajchman A, Stephenson M, Eliopoulos C, Koren G. Prospective follow-up of adverse reactions in breast-fed infants exposed to maternal medication. Am J Obstet Gynecol. 1993;168(5):1393-1399.
114. Chan WS, Dixon ME. The "ART" of thromboembolism: a review of assisted reproductive technology and thromboembolic complications. Thromb Res. 2008;121(6):713-726.
115. Nelson SM. Prophylaxis of VTE in women-during assisted reproductive techniques. Thromb Res. 2009; 123(suppl 3):S8- S15.
116. Mára M, Koryntová D, Rezábek K, et al. Thromboembolic complications in patients undergoing in vitro fertilization: retrospective clinical study [in Czech]. Ceska Gynekol. 2004;69(4):312-316.
117. Aurousseau MH, Samama MM, Belhassen A, Herve F, Hugues JN. Risk of thromboembolism in relation to an in-vitro fertilization programme: three case reports. Hum Reprod. 1995;10(1):94-97.
118. Delvigne A, Demoulin A, Smitz J, et al. The ovarian hyperstimulation syndrome in in-vitro fertilization: a Belgian multicentric study. I. Clinical and biological features. Hum Reprod. 1993;8(9):1353-1360.
119. Morris RS, Miller C, Jacobs L, Miller K. Conservative management of ovarian hyperstimulation syndrome. J Reprod Med. 1995;40(10):711-714.
120. Bergh T, Lundkvist O. Clinical complications during in-vitro fertilization treatment. Hum Reprod. 1992;7(5):625-626.
121. Jacobsen AF, Skjeldestad FE, Sandset PM. Ante- and postnatal risk factors of venous thrombosis: a hospital-based case-control study. J Thromb Haemost. 2008;6(6):905-912.
122. Chan WS. The 'ART' of thrombosis: a review of arterial and venous thrombosis in assisted reproductive technology. Curr Opin Obstet Gynecol. 2009;21(3):207-218.
123. Dessole S, Rubattu G, Ambrosini G, Miele M, Nardelli GB, Cherchi PL. Blood loss following noncomplicated transvaginal oocyte retrieval for in vitro fertilization. Fertil Steril. 2001;76(1):205-206.
124. Shalev J, Davidi O, Fisch B. Quantitative three-dimensional sonographic assessment of pelvic blood after transvaginal ultrasound-guided oocyte aspiration: factors predicting risk. Ultrasound Obstet Gynecol. 2004;23(2):177-182.
125. Ragni G, Scarduelli C, Calanna G, Santi G, Benaglia L, Somigliana E. Blood loss during transvaginal oocyte retrieval. Gynecol Obstet Invest. 2009;67(1):32-35.
126. Bennett SJ, Waterstone JJ, Cheng WC, Parsons J. Complications of transvaginal ultrasound-directed follicle aspiration: a review of 2760 consecutive procedures. J Assist Reprod Genet. 1993;10(1):72-77.
127. Dicker D, Ashkenazi J, Feldberg D, Levy T, Dekel A, Ben-Rafael Z. Severe abdominal complications after transvaginal ultrasonographically guided retrieval of oocytes for in vitro fertilization and embryo transfer. Fertil Steril. 1993;59(6):1313-1315.
128. Tureck RW, García CR, Blasco L, Mastroianni L Jr. Perioperative complications arising after transvaginal oocyte retrieval. Obstet Gynecol. 1993;81(4):590-593.
129. Govaerts I, Devreker F, Delbaere A, Revelard P, Englert Y. Short-term medical complications of 1500 oocyte retrievals for in vitro fertilization and embryo transfer. Eur J Obstet Gynecol Reprod Biol. 1998;77(2):239-243.
130. Ludwig AK, Glawatz M, Griesinger G, Diedrich K, Ludwig M. Perioperative and post-operative complications of transvaginal ultrasound-guided oocyte retrieval: prospective study of. 1000 oocyte retrievals. Hum Reprod. 2006;21(12):3235-3240.
131. Bodri D, Guillén JJ, Polo A, Trullenque M, Esteve C, Coll O. Complications related to ovarian stimulation and oocyte retrieval in 4052 oocyte donor cycles. Reprod Biomed Online. 2008;17(2):237-243.
132. Baber R, Porter R, Picker R, Robertson R, Dawson E, Saunders D. Transvaginal ultrasound directed oocyte collection for in vitro fertilization: successes and complications. J Ultrasound Med. 1988;7(7):377-379.
133. Yinon Y, Pauzner R, Dulitzky M, Elizur SE, Dor J, Shulman A. Safety of IVF under anticoagulant therapy in patients at risk for thrombo-embolic events. Reprod Biomed Online. 2006;12(3):354-358.
134. Qublan H, Amarin Z, Dabbas M, et al. Low-molecular-weight heparin in the treatment of recurrent IVF-ET failure and thrombophilia: a prospective randomized placebo-controlled trial. Hum Fertil. 2008;11(4):246-253.
135. Stern C, Chamley L, Norris H, Hale L, Baker HW. A randomized, double-blind, placebo-controlled trial of heparin and aspirin for women with in vitro fertilization implantation failure and antiphospholipid or antinuclear antibodies. Fertil Steril. 2003;80(2):376-383.
136. Hull RD, Pineo GF, Stein PD, et al. Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review. Ann Intern Med. 2001;135(10):858- 869.
137. Pomp ER, Lenselink AM, Rosendaal FR, Doggen CJ. Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study. J Thromb Haemost. 2008;6(4):632-637.
138. Heit JA, Kobbervig CE, James AH, Petterson TM, Bailey KR, Melton LJ III. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med. 2005; 143(10):697-706.
139. Gherman RB, Goodwin TM, Leung B, Byrne JD, Hethumumi R, Montoro M. Incidence, clinical characteristics, and timing of objectively diagnosed venous thromboembolism during pregnancy. Obstet Gynecol. 1999; 94(5 pt 1):730-734.
140. Macklon NS, Greer IA. Venous thromboembolic disease in obstetrics and gynaecology: the Scottish experience. Scott Med J. 1996;41(3):83-86.
141. Blondon MB, Perrier A, Nendaz M, et al. Thromboprophylaxis with low-molecular-weight heparin after cesarean delivery. Thromb Haemost. 2010;103(1):129-137.
142. Bergqvist A, Bergqvist D, Hallböök T. Acute deep vein thrombosis (DVT) after cesarean section. Acta Obstet Gynecol Scand. 1979;58(5):473-476.
143. Chan LY, Lam KY, Metreweli C, Lau TK. Duplex ultrasound screening for deep vein thrombosis in Chinese after cesarean section. Acta Obstet Gynecol Scand. 2005;84(4):368-370.
144. Jacobsen AF, Drolsum A, Klow NE, Dahl GF, Qvigstad E, Sandset PM. Deep vein thrombosis after elective cesarean section. Thromb Res. 2004;113(5):283-288.
145. Kalro BN, Davidson RA, Owen P. Low incidence of asymptomatic deep venous thrombosis following caesarean section: a colour Doppler study. Health Bull (Edinb). 1999; 57(6):418-421.
146. Lindqvist P, Dahlbäck B, Marál K. Thrombotic risk during pregnancy: a population study. Obstet Gynecol. 1999;94(4):595-599.
147. Sia WW, Powrie RO, Cooper AB, et al. The incidence of deep vein thrombosis in women undergoing cesarean delivery. Thromb Res. 2009;123(3):550-555.
148. Simpson EL, Lawrenson RA, Nightingale AL, Farmer RD. Venous thromboembolism in pregnancy and the puerperium: incidence and additional risk factors from a London perinatal database. BJOG. 2001;108(1):56-60.
149. White RH, Brickner LA, Scannell KA. ICD-9-CM codes poorly indentified venous thromboembolism during pregnancy. J Clin Epidemiol. 2004;57(9):985-988.
150. Knight M;UKOSS. Antenatal pulmonary embolism: risk factors, management and outcomes. BJOG. 2008;115(4):453-461.
151. Robertson L, Wu O, Langhorne P, et al Thrombosis Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study. Thrombophilia in pregnancy: a systematic review. Br J Haematol. 2005;132(2):1 71-196.
152. James AH, Jamison MG, Brancazio LR, Myers ER. Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. Am J Obstet Gynecol. 2006;194(5):1311-1315.
153. McColl MD, Ramsay JE, Tait RC, et al. Risk factors for pregnancy associated venous thromboembolism. Thromb Haemost. 1997;78(4):1183-1188.
154. Einstein MH, Kushner DM, Connor JP, et al. A protocol of dual prophylaxis for venous thromboembolism prevention in gynecologic cancer patients. Obstet Gynecol. 2008;112(5):1091-1097.
155. Kakkos SK, Caprini JA, Geroulakos G, Nicolaides AN, Stansby GP, Reddy DJ. Combined intermittent pneumatic leg compression and pharmacological prophylaxis for prevention of venous thromboembolism in high-risk patients. Cochrane Database Syst Rev. 2008;(4):CD005258.
156. Gould MK, Garcia DA, Wren SM, et al. Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2)(suppl):e227S-e277S.
157. Tooher R, Gates S, Dowswell T, Davis LJ. Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period. Cochrane Database Syst Rev. 2010;5(5):CD001689.
158. Gates S, Brocklehurst P, Ayers S, Bowler U; Thromboprophylaxis in Pregnancy Advisory Group. Thromboprophylaxis and pregnancy: two randomized controlled pilot trials that used low-molecular-weight heparin. Am J Obstet Gynecol. 2004;191(4):1296-1303.
159. Burrows RF, Gan ET, Gallus AS, Wallace EM, Burrows EA. A randomised double-blind placebo controlled trial of low molecular weight heparin as prophylaxis in preventing venous thrombolic events after caesarean section: a pilot study. BJOG. 2001;108(8):835-839.
160. Hill NC, Hill JG, Sargent JM, Taylor CG, Bush PV. Effect of low dose heparin on blood loss at caesarean section. BMJ. 1988;296(6635):505-506.
161. Welti H. Prophylaxie thrombo-embolique par physiotherapie avec et sans heparine a faibles doses en gynecologieobstetrique. Rev Med Suisse Romande. 1981; 101(11):925- 934.
162. Mismetti P, Laporte S, Darmon JY, Buchmüller A, Decousus H. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg. 2001;88(7):913-930.
163. White RH, Zhou H, Romano PS. Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures. Thromb Haemost. 2003;90(3):446-455.
164. Bergqvist D. Prolonged prophylaxis in postoperative medicine. Semin Thromb Hemost. 1997;23(2):149-154.
165. Bergqvist D, Agnelli G, Cohen AT, et al; ENOXACAN II Investigators. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med. 2002;346(13):975-980.
166. Rasmussen MS, Jorgensen LN, Wille-Jørgensen P, et al FAME Investigators. Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open-label study. J Thromb Haemost. 2006;4(11):2384-2390.
167. Casele H, Grobman WA. Cost-effectiveness of thromboprophylaxis with intermittent pneumatic compression at cesarean delivery. Obstet Gynecol. 2006; 108(3 pt 1):535- 540.
168. Chang J, Elam-Evans LD, Berg CJ, et al. Pregnancy-related mortality surveillance-United States, 1991-1999. MMWR Surveill Summ. 2003;52(2):1-8.
169. Lewis G, ed. C onfidential Enquiry Into Maternal and Child Health. Saving Mothers' Lives-Reviewing Maternal Deaths To Make Motherhood Safer 2003-2005. London, England: CEMACH; 2007.
170. McColl MD, Ellison J, Greer IA, Tait RC, Walker ID. Prevalence of the post-thrombotic syndrome in young women with previous venous thromboembolism. Br J Haematol. 2000;108(2):272-274.
171. Rosfors S, Norén A, Hjertberg R, Persson L, Lillthors K, Törngren S. A 16-year haemodynamic follow-up of women with pregnancy-related medically treated iliofemoral deep venous thrombosis. Eur J Vasc Endovasc Surg. 2001; 22(5):448-455.
172. Andersen BS, Steffensen FH, Sørensen HT, Nielsen GL, Olsen J. The cumulative incidence of venous thromboembolism during pregnancy and puerperium - an 11 year Danish population-based study of 63,300 pregnancies. Acta Obstet Gynecol Scand. 1998;77(2):170-173.
173. Ray JG, Chan WS. Deep vein thrombosis during pregnancy and the puerperium: a meta-analysis of the period of risk and the leg of presentation. Obstet Gynecol Surv. 1999;54(4):265-271.
174. Voke J, Keidan J, Pavord S, Spencer HN, Hunt BJ; British Society of Haematology Obstetric Haematology Group. The management of antenatal venous thromboembolism in the UK and Ireland: a prospective multicentre observational study. Br J Haematol. 2007;139 (4):545-558.
175. Lopaciuk S, Bielska-Falda H, Noszczyk W, et al. Low-molecular-weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis. Thromb Haemost. 1999;81(1):26-31.
176. Hutten BA, Büller HR, Prins MH, van Der Heijden JF. Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism. Cochrane Database Syst Rev. 2000;(4):CD002001.
177. Lee AYY, Levine MN, Baker RI, et al Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349(2):146-153.
178. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2)(suppl):e419S-e494S.
179. Prandoni P, Lensing AWA, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;100(10):3484-3488.
180. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med. 1998;105(2):91-99.
181. Crowther MA, Spitzer K, Julian J, et al. Pharmacokinetic profile of a low-molecular weight heparin (reviparin) in pregnant patients. A prospective cohort study. Thromb Res. 2000;98(2):133-138.
182. Barbour LA, Oja JL, Schultz LK. A prospective trial that demonstrates that dalteparin requirements increase in pregnancy to maintain therapeutic levels of anticoagulation. Am J Obstet Gynecol. 2004;191(3):1024-1029.
183. Jacobsen AF, Qvigstad E, Sandset PM. Low molecular weight heparin (dalteparin) for the treatment of venous thromboembolism in pregnancy. BJOG. 2003; 110(2):139- 144.
184. Rodie VA, Thomson AJ, Stewart FM, Quinn AJ, Walker ID, Greer IA. Low molecular weight heparin for the treatment of venous thromboembolism in pregnancy: a case series. BJOG. 2002;109(9):1020-1024.
185. Rey E, Rivard GE. Prophylaxis and treatment of thromboembolic diseases during pregnancy with dalteparin. Int J Gynaecol Obstet. 2000;71(1):19-24.
186. Smith MP, Norris LA, Steer PJ, Savidge GF, Bonnar J. Tinzaparin sodium for thrombosis treatment and prevention during pregnancy. Am J Obstet Gynecol. 2004;190(2):495- 501.
187. Kovacs MJ, Keeney M, MacKinnon K, Boyle E. Three different chromogenic methods do not give equivalent anti-Xa levels for patients on therapeutic low molecular weight heparin (dalteparin) or unfractionated heparin. Clin Lab Haematol. 1999;21(1):55-60.
188. Garcia DA, Baglin TP, Weitz JI, Samama MM. Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2)(suppl):e24S-e43S.
189. Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2)(suppl):e326S-e350S.
190. Chargaff E, Olson KB. Studies on chemistry of blood coagulation. VI. Studies on the action of heparin and other anticoagulants. The influence of protamine on the anticoagulant effect in vivo. J Biol Chem. 1937;122:163-167.
191. Massonnet-Castel S, Pelissier E, Bara L, et al. Partial reversal of low molecular weight heparin (PK 10169) anti-Xa activity by protamine sulfate: in vitro and in vivo study during cardiac surgery with extracorporeal circulation. Haemostasis. 1986;16(2):139-146.
192. Gupta S, Ettles DF, Robinson GJ, Lindow SW. Inferior vena cava filter use in pregnancy: preliminary experience. BJOG. 2008;115(6):785-788.
193. Cheung MC, Asch MR, Gandhi S, Kingdom JCP. Temporary inferior vena caval filter use in pregnancy. J Thromb Haemost. 2005;3(5):1096-1097.
194. Ganguli S, Tham JC, Komlos F, Rabkin DJ. Fracture and migration of a suprarenal inferior vena cava filter in a pregnant patient. J Vasc Interv Radiol. 2006;17(10):1707-1711.
195. López JA, Kearon C, Lee AY. Deep venous thrombosis. Hematology (Am Soc Hematol Educ Program). 2004:439-456.
196. Pabinger I, Grafenhofer H, Kyrle PA, et al. Temporary increase in the risk for recurrence during pregnancy in women with a history of venous thromboembolism. Blood. 2002;100(3):1060-1062.
197. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 suppl):311S-337S.
198. Badaracco MA, Vessey MP. Recurrence of venous thromboembolic disease and use of oral contraceptives. BMJ. 1974;1(5901):215-217.
199. Tengborn L, Bergqvist D, Mätzsch T, Bergqvist A, Hedner U. Recurrent thromboembolism in pregnancy and puerperium. Is there a need for thromboprophylaxis? Am J Obstet Gynecol. 1989;160(1):90-94.
200. Lao TT, de Swiet M, Letsky SE, Walters BN. Prophylaxis of thromboembolism in pregnancy: an alternative. Br J Obstet Gynaecol. 1985;92(3):202-206.
201. de Swiet M, Floyd E, Letsky E. Low risk of recurrent thromboembolism in pregnancy. Br J Hosp Med. 1987;38(3):264.
202. Howell R, Fidler J, Letsky E, de Swiet M. The risks of antenatal subcutaneous heparin prophylaxis: a controlled trial. Br J Obstet Gynaecol. 1983;90(12):1124-1128.
203. Brill-Edwards P, Ginsberg JS, Gent M, et al Recurrence of Clot in This Pregnancy Study Group. Safety of withholding heparin in pregnant women with a history of venous thromboembolism . N Engl J Med. 2000;343(20):1439-1444.
204. Pabinger I, Grafenhofer H, Kaider A, et al. Risk of pregnancy-associated recurrent venous thromboembolism in women with a history of venous thrombosis. J Thromb Haemost. 2005;3(5):949-954.
205. De Stefano V, Martinelli I, Rossi E, et al. The risk of recurrent venous thromboembolism in pregnancy and puerperium without antithrombotic prophylaxis. Br J Haematol. 2006;135(3):386-391.
206. White RH, Chan WS, Zhou H, Ginsberg JS. Recurrent venous thromboembolism after pregnancy-associated versus unprovoked thromboembolism. Thromb Haemost. 2008;100(2):246-252.
207. Pettilä V, Kaaja R, Leinonen P, Ekblad U, Kataja M, Ikkala E. Thromboprophylaxis with low molecular weight heparin (dalteparin) in pregnancy. Thromb Res. 1999;96(4):275-282.
208. Rozanski C, Lazo-Langner A, Kovacs M. Prevention of venous thromboembolism (VTE) associated with pregnancy in women with a past history of VTE [abstract]. Blood. 2009;114(suppl):3132.
209. Blombäck M, Bremme K, Hellgren M, Siegbahn A, Lindberg H. Thromboprophylaxis with low molecular mass heparin, 'Fragmin' (dalteparin), during pregnancy-a longitudinal safety study. Blood Coagul Fibrinolysis. 1998;9(1):1-9.
210. Brennand JE, Walker ID, Greer IA. Anti-activated factor X profiles in pregnant women receiving antenatal thromboprophylaxis with enoxaparin. Acta Haematol. 1999; 101(1):53-55.
211. Dargaud Y, Rugeri L, Vergnes MC, et al. A risk score for the management of pregnant women with increased risk of venous thromboembolism: a multicentre prospective study. Br J Haematol. 2009;145(6):825-835.
212. Folkeringa N, Brouwer JL, Korteweg FJ, Veeger NJ, Erwich JJ, van der Meer J. High risk of pregnancy-related venous thromboembolism in women with multiple thrombophilic defects. Br J Haematol. 2007;138(1):110-116.
213. Dulitzki M, Pauzner R, Langevitz P, Pras M, Many A, Schiff E. Low-molecular-weight heparin during pregnancy and delivery: preliminary experience with 41 pregnancies. Obstet Gynecol. 1996;87(3):380-383.
214. Casele HL, Laifer SA, Woelkers DA, Venkataramanan R. Changes in the pharmacokinetics of the low-molecular-weight heparin enoxaparin sodium during pregnancy. Am J Obstet Gynecol. 1999;181(5 pt 1):1113-1117.
215. Ellison J, Thomson AJ, Conkie JA, McCall F, Walker D, Greer A. Thromboprophylaxis following caesarean section - a comparison of the antithrombotic properties of three low molecular weight heparins - dalteparin, enoxaparin and tinzaparin. Thromb Haemost. 2001;86(6):1374-1378.
216. Roeters van Lennep JE, Meijer E, Klumper FJ, Middeldorp JM, Bloemenkamp KW, Middeldorp S. Prophylaxis with low-dose low-molecular-weight heparin during pregnancy and postpartum: is it effective? J Thromb Haemost. 2011;9(3):473-480.
217. Kitchen S, Iampietro R, Woolley AM, Preston FE. Anti Xa monitoring during treatment with low molecular weight heparin or danaparoid: inter-assay variability. Thromb Haemost. 1999;82(4):1289-1293.
218. Bates SM, Jaeschke R, Stevens SM, et al. Diagnosis of DVT: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2)(suppl):e351S-e418S.
219. Friederich PW, Sanson BJ, Simioni P, et al. Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient women: implications for prophylaxis. Ann Intern Med. 1996;125(12):955-960.
220. Middeldorp S, Henkens CMA, Koopman MMW, et al. The incidence of venous thromboembolism in family members of patients with factor V Leiden mutation and venous thrombosis. Ann Intern Med. 1998;128(1):15-20.
221. Simioni P, Sanson BJ, Prandoni P, et al. Incidence of venous thromboembolism in families with inherited thrombophilia. Thromb Haemost. 1999;81(2):198-202.
222. Middeldorp S, Meinardi JR, Koopman MMW, et al. A prospective study of asymptomatic carriers of the factor V Leiden mutation to determine the incidence of venous thromboembolism. Ann Intern Med. 2001;135(5):322-327.
223. Couturaud F, Leroyer C, Mottier D; Groupe dEtude de la Thrombose de Bretagne Occidentale (G.E.T.B.O). Risk factors and clinical presentation of venous thromboembolism according to the age of relatives of patients with factor V Leiden. Thromb Haemost. 2008;99(4):793-794.
224. Middeldorp S, Libourel EJ, Hamulyak K, van der MJ, Buller HR. The risk of pregnancy-related venous thromboembolism in women who are homozygous for factor V Leiden. Br J Haematol. 2001;113(2):553-555.
225. Martinelli I, Legnani C, Bucciarelli P, Grandone E, De Stefano V, Mannucci PM. Risk of pregnancy-related venous thrombosis in carriers of severe inherited thrombophilia. Thromb Haemost. 2001;86(3):800-803.
226. Tormene D, Simioni P, Prandoni P, et al. Factor V Leiden mutation and the risk of venous thromboembolism in pregnant women. Haematologica. 2001;86(12):1305-1309.
227. Bank I, Libourel EJ, Middeldorp S, et al. Prothrombin 20210A mutation: a mild risk factor for venous thromboembolism but not for arterial thrombotic disease and pregnancy-related complications in a family study. Arch Intern Med. 2004;164(17):1932-1937.
228. Coppens M, van de Poel MH, Bank I, et al. A prospective cohort study on the absolute incidence of venous thromboembolism and arterial cardiovascular disease in asymptomatic carriers of the prothrombin 20210A mutation. Blood. 2006;108(8):2604-2607.
229. Biron-Andreani C, Schved JF, Daures JP, Factor V Leiden mutation and pregnancy-related venous thromboembolism: what is the exact risk? Results from a meta-analysis. Thromb Haemost. 2006;96(1):14-18.
230. Bezemer ID, van der Meer FJ, Eikenboom JC, Rosendaal FR, Doggen CJ. The value of family history as a risk indicator for venous thrombosis. Arch Intern Med. 2009;169(6):610-615.
231. Simioni P, Tormene DF, Prandoni PF, et al. Incidence of venous thromboembolism in asymptomatic family members who are carriers of factor V Leiden: a prospective cohort study. Blood. 2002;99(6):1938-1942.
232. De Stefano V, Martinelli I, Mannucci PM, et al. The risk of recurrent venous thromboembolism among heterozygous carriers of the G20210A prothrombin gene mutation. Br J Haematol. 2001;113(3):630-635.
233. Conard J, Horellou MH, Van Dreden P, Lecompte T, Samama M. Thrombosis and pregnancy in congenital deficiencies in AT III, protein C or protein S: study of 78 women. Thromb Haemost. 1990;63(2):319-320.
234. Martinelli I, Battaglioli T, De Stefano V, et al GIT (Gruppo Italiano Trombofilia). The risk of first venous thromboembolism during pregnancy and puerperium in double heterozygotes for factor V Leiden and prothrombin G20210A. J Thromb Haemost. 2008;6(3):494-498.
235. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295-306.
236. Galli M, Barbui T. Antiphospholipid syndrome: clinical and diagnostic utility of laboratory tests. Semin Thromb Hemost. 2005;31(1):17-24.
237. Bergrem A, Jacobsen EM, Skjeldestad FE, Jacobsen AF, Skogstad M, Sandset PM. The association of antiphospholipid antibodies with pregnancy-related first time venous thrombosis-a population-based case-control study. Thromb Res. 2010;125(5):e222-e227.
238. Quenby S, Farquharson RG, Dawood F, Hughes AM, Topping J. Recurrent miscarriage and long-term thrombosis risk: a case-control study. Hum Reprod. 2005;20(6):1729- 1732.
239. den Heijer M, Koster T, Blom HJ, et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med. 1996;334(12):759-762.
240. Greer IA. The challenge of thrombophilia in maternal-fetal medicine. N Engl J Med. 2000;342(6):424-425.
241. Broekmans AW, Bertina RM, Loeliger EA, Hofmann V, Klingemann HG. Protein C and the development of skin necrosis during anticoagulant therapy. Thromb Haemost. 1983;49(3):251.
242. Locht H, Lindström FD. Severe skin necrosis following warfarin therapy in a patient with protein C deficiency. J Intern Med. 1993;233(3):287-289.
243. Berkompas DC. Coumadin skin necrosis in a patient with a free protein S deficiency: case report and literature review. Indiana Med. 1991;84(11):788-791.
244. Rai R, Regan L. Recurrent miscarriage. Lancet. 2006;368(9535):601-611.
245. Nelson SM, Greer IA. The potential role of heparin in assisted conception. Hum Reprod Update. 2008;14(6):623-645.
246. Bose P, Black S, Kadyrov M, et al. Heparin and aspirin attenuate placental apoptosis in vitro: implications for early pregnancy failure. Am J Obstet Gynecol. 2005; 192(1):23- 30.
247. Di Simone N, Caliandro D, Castellani R, Ferrazzani S, De Carolis S, Caruso A. Low-molecular weight heparin restores in-vitro trophoblast invasiveness and differentiation in presence of immunoglobulin G fractions obtained from patients with antiphospholipid syndrome. Hum Reprod. 1999;14(2):489-495.
248. Ganapathy R, Whitley GS, Cartwright JE, Dash PR, Thilaganathan B. Effect of heparin and fractionated heparin on trophoblast invasion. Hum Reprod. 2007;22(9):2523-2527.
249. Ginsberg JS, Brill-Edwards P, Johnston M, et al. Relationship of antiphospholipid antibodies to pregnancy loss in patients with systemic lupus erythematosus: a cross-sectional study. Blood. 1992;80(4):975-980.
250. Laskin CA, Bombardier C, Hannah ME, et al. Prednisone and aspirin in women with autoantibodies and unexplained recurrent fetal loss. N Engl J Med. 1997;337(3):148-153.
251. Rai RS, Clifford K, Cohen H, Regan L. High prospective fetal loss rate in untreated pregnancies of women with recurrent miscarriage and antiphospholipid antibodies. Hum Reprod. 1995;10(12):3301-3304.
252. Empson M, Lassere M, Craig JC, Scott JR. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. Cochrane Database Syst Rev. 2005;(2):CD002859.
253. Opatrny L, David M, Kahn SR, Shrier I, Rey E. Association between antiphospholipid antibodies and recurrent fetal loss in women without autoimmune disease: a metaanalysis. J Rheumatol. 2006;33(11):2214-2221.
254. Branch DW, Andres R, Digre KB, Rote NS, Scott JR. The association of antiphospholipid antibodies with severe preeclampsia. Obstet Gynecol. 1989;73(4):541-545.
255. Polzin WJ, Kopelman JN, Robinson RD, Read JA, Brady K. The association of antiphospholipid antibodies with pregnancies complicated by fetal growth restriction. Obstet Gynecol. 1991;78(6):1108-1111.
256. Lockwood CJ, Romero R, Feinberg RF, Clyne LP, Coster B, Hobbins JC. The prevalence and biologic significance of lupus anticoagulant and anticardiolipin antibodies in a general obstetric population. Am J Obstet Gynecol. 1989;161(2):369-373.
257. Lockshin MD, Druzin ML, Goei S, et al. Antibody to cardiolipin as a predictor of fetal distress or death in pregnant patients with systemic lupus erythematosus. N Engl J Med. 1985;313(3):152-156.
258. Reece EA, Gabrielli S, Cullen MT, Zheng XZ, Hobbins JC, Harris EN. Recurrent adverse pregnancy outcome and antiphospholipid antibodies. Am J Obstet Gynecol. 1990;163(1 pt 1):162-169.
259. Milliez J, Lelong F, Bayani N, et al. The prevalence of autoantibodies during third-trimester pregnancy complicated by hypertension or idiopathic fetal growth retardation. Am J Obstet Gynecol. 1991;165(1):51-56.
260. el-Roeiy A, Myers SA, Gleicher N. The relationship between autoantibodies and intrauterine growth retardation in hypertensive disorders of pregnancy. Am J Obstet Gynecol. 1991;164(5 pt 1):1253-1261.
261. von Tempelhoff GF, Heilmann L, Spanuth E, Kunzmann E, Hommel G. Incidence of the factor V Leidenmutation, coagulation inhibitor deficiency, and elevated antiphospholipid-antibodies in patients with preeclampsia or HELLP-syndrome. Hemolysis, elevated liver-enzymes, low platelets. Thromb Res. 2000;100(4):363-365.
262. Sletnes KE, Wisløff F, Moe N, Dale PO. Antiphospholipid antibodies in pre-eclamptic women: relation to growth retardation and neonatal outcome. Acta Obstet Gynecol Scand. 1992;71(2):112-117.
263. Lynch A, Marlar R, Murphy J, et al. Antiphospholipid antibodies in predicting adverse pregnancy outcome. A prospective study. Ann Intern Med. 1994;120(6):470-475.
264. Harris EN, Spinnato JA. Should anticardiolipin tests be performed in otherwise healthy pregnant women? Am J Obstet Gynecol. 1991;165(5 pt 1):1272-1277.
265. Branch DW, Porter TF, Rittenhouse L, et al National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Antiphospholipid antibodies in women at risk for preeclampsia. Am J Obstet Gynecol. 2001;184(5):825-832, discussion 832-834.
266. Out HJ, Bruinse HW, Christiaens GC, et al. A prospective, controlled multicenter study on the obstetric risks of pregnant women with antiphospholipid antibodies. Am J Obstet Gynecol. 1992;167(1):26-32.
267. Faux JA, Byron MA, Chapel HM. Clinical relevance of specific IgG antibodies of cardiolipin. Lancet. 1989;2(8677):1457-1458.
268. Taylor PV, Skerrow SM, Redman CW. Pre-eclampsia and anti-phospholipid antibody. Br J Obstet Gynaecol. 1991;98(6):604-606.
269. Sanson BJ, Friederich PW, Simioni P, et al. The risk of abortion and stillbirth in antithrombin-, protein C-, and protein S-deficient women. Thromb Haemost. 1996;75(3):387-388.
270. Preston FE, Rosendaal FR, Walker ID, et al. Increased fetal loss in women with heritable thrombophilia. Lancet. 1996;348(9032):913-916.
271. Meinardi JR, Middeldorp S, de Kam PJ, et al. Increased risk for fetal loss in carriers of the factor V Leiden mutation. Ann Intern Med. 1999;130(9):736-739.
272. Tormene D, Simioni P, Prandoni P, et al. The risk of fetal loss in family members of probands with factor V Leiden mutation. Thromb Haemost. 1999;82(4):1237-1239.
273. Middeldorp S, van de Poel MH, Bank I, et al. Unselected women with elevated levels of factor VIII:C or homocysteine are not at increased risk for obstetric complications. Thromb Haemost. 2004;92(4):787-790.
274. Rey E, Kahn SR, David M, Shrier I. Thrombophilic disorders and fetal loss: a meta-analysis. Lancet. 2003;361(9361):901-908.
275. Morrison ER, Miedzybrodzka ZH, Campbell DM, et al. Prothrombotic genotypes are not associated with pre-eclampsia and gestational hypertension: results from a large population-based study and systematic review. Thromb Haemost. 2002;87(5):779-785.
276. Pabinger I, Vormittag R. Thrombophilia and pregnancy outcomes. J Thromb Haemost. 2005;3(8):1603-1610.
277. Rodger MA, Betancourt MT, Clark P, et al. The association of factor V Leiden and prothrombin gene mutation and placenta-mediated pregnancy complications: a systematic review and meta-analysis of prospective cohort studies. PLoS Med. 2010;7(6):e1000292.
278. Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol. 1996;174(5):1584-1589.
279. Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ. 1997;314(7076):253-257.
280. Kutteh WH, Ermel LD. A clinical trial for the treatment of antiphospholipid antibody-associated recurrent pregnancy loss with lower dose heparin and aspirin. Am J Reprod Immunol. 1996;35(4):402-407.
281. Cowchock S, Reece EA. Do low-risk pregnant women with antiphospholipid antibodies need to be treated? Organizing Group of the Antiphospholipid Antibody Treatment Trial. Am J Obstet Gynecol. 1997;176(5):1099-1100.
282. Pattison NS, Chamley LW, Birdsall M, Zanderigo AM, Liddell HS, McDougall J. Does aspirin have a role in improving pregnancy outcome for women with the antiphospholipid syndrome? A randomized controlled trial. Am J Obstet Gynecol. 2000;183(4):1008-1012.
283. Tulppala M, Marttunen M, Söderstrom-Anttila V, et al. Low-dose aspirin in prevention of miscarriage in women with unexplained or autoimmune related recurrent miscarriage: effect on prostacyclin and thromboxane A2 production. Hum Reprod. 1997;12(7):1567-1572.
284. Farquharson RG, Quenby S, Greaves M. Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstet Gynecol. 2002;100(3):408-413.
285. Noble LS, Kutteh WH, Lashey N, Franklin RD, Herrada J. Antiphospholipid antibodies associated with recurrent pregnancy loss: prospective, multicenter, controlled pilot study comparing treatment with low-molecular-weight heparin versus unfractionated heparin. Fertil Steril. 2005; 83(3):684-690.
286. Stephenson MD, Ballem PJ, Tsang P, et al. Treatment of antiphospholipid antibody syndrome (APS) in pregnancy: a randomized pilot trial comparing low molecular weight heparin to unfractionated heparin. J Obstet Gynaecol Can. 2004;26(8):729-734.
287. Gris JC, Quéré I, Monpeyroux F, et al. Case-control study of the frequency of thrombophilic disorders in couples with late foetal loss and no thrombotic antecedent-the Nîmes Obstetricians and Haematologists Study 5 (NOHA5). Thromb Haemost. 1999;81(6):891-899.
288. Carp H, Dolitzky M, Inbal A. Thromboprophylaxis improves the live birth rate in women with consecutive recurrent miscarriages and hereditary thrombophilia. J Thromb Haemost. 2003;1(3):433-438.
289. Kupferminc MJ, Fait G, Many A, et al. Low-molecular-weight heparin for the prevention of obstetric complications in women with thrombophilias. Hypertens Pregnancy. 2001;20(1):35-44.
290. Goel N, Tuli A, Choudhry R. The role of aspirin versus aspirin and heparin in cases of recurrent abortions with raised anticardiolipin antibodies. Med Sci Monit. 2006;12(3):CR132-CR136.
291. Triolo G, Ferrante A, Ciccia F, et al. Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulin in the treatment of recurrent fetal loss associated with antiphospholipid antibodies. Arthritis Rheum. 2003;48(3):728-731.
292. Mak A, Cheung MW-L, Cheak AA, Ho RC. Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive anti-phospholipid antibodies: a meta-analysis of randomized controlled trials and meta-regression. Rheumatology (Oxford). 2010;49(2):281-288.
293. Laskin CA, Spitzer KA, Clark CA, et al. Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA Trial. J Rheumatol. 2009;36(2):279-287.
294. Brenner B, Hoffman R, Blumenfeld Z, Weiner Z, Younis JS. Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin. Thromb Haemost. 2000;83(5):693-697.
295. Brenner B, Hoffman R, Carp H, Dulitsky M, Younis J; LIVE-ENOX Investigators. Efficacy and safety of two doses of enoxaparin in women with thrombophilia and recurrent pregnancy loss: the LIVE-ENOX study. J Thromb Haemost. 2005;3(2):227-229.
296. Brenner B, Bar J, Ellis M, Yarom I, Yohai D, Samueloff A; Live-Enox Investigators. Effects of enoxaparin on late pregnancy complications and neonatal outcome in women with recurrent pregnancy loss and thrombophilia: results from the Live-Enox study. Fertil Steril. 2005;84(3):770-773.
297. Gris JC, Mercier E, Quéré I, et al. Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood. 2004;103(10):3695-3699.
298. Tzafettas J, Petropoulos P, Psarra A, et al. Early antiplatelet and antithrombotic therapy in patients with a history of recurrent miscarriages of known and unknown aetiology. Eur J Obstet Gynecol Reprod Biol. 2005;120(1):22-26.
299. Leduc L, Dubois E, Takser L, Rey E, David MJ. Dalteparin and low-dose aspirin in the prevention of adverse obstetric outcomes in women with inherited thrombophilia. J Obstet Gynaecol Can. 2007;29(10):787-793.
300. Middeldorp S. Thrombophilia and pregnancy complications: cause or association? J Thromb Haemost. 2007;5(suppl 1):276- 282.
301. Walker ID, Kujovich JL, Greer IA, et al. The use of LMWH in pregnancies at risk: new evidence or perception? J Thromb Haemost. 2005;3(4):778-793.
302. Lindqvist PG, Merlo J. Low molecular weight heparin for repeated pregnancy loss: is it based on solid evidence? J Thromb Haemost. 2005;3(2):221-223.
303. Rodger M. Important publication missing key information. Blood. 2004;104(10):3413, author reply 3413-3414.
304. Gris JC, Quere I, Dauzat M, Mares P. Response: thromboprophylaxis for first fetal loss. Blood. 2004;104(10):3413-3414
305. Rodger MA, Paidas MJ, McLintock C, et al. Inherited thrombophilia and pregnancy complications revisited. Obstet Gynecol. 2008;112(2 pt 1):320-324.
306. Coppens M, Folkeringa N, Teune M, et al. Natural course of the subsequent pregnancy after a single loss in women with and without the factor V Leiden or prothrombin 20210A mutations. J Thromb Haemost. 2007;5(7):1444-1448.
307. Sheppard BL, Bonnar J. An ultrastructural study of uteroplacental spiral arteries in hypertensive and normotensive pregnancy and fetal growth retardation. Br J Obstet Gynaecol. 1981;88(7):695-705.
308. Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. Lancet. 2010;376(9741):631-644.
309. Young BC, Levine RJ, Karumanchi SA. Pathogenesis of preeclampsia. Annu Rev Pathol. 2010;5:173-192.
310. Greer IA. Platelets and coagulation abnormalities in preeclampsia. In: Rubin P, ed. Handbook of Hypertension: Hypertension in Pregnancy. Amsterdam, The Netherlands: Elsevier Science;1999:163-181.
311. Sattar N, Greer IA. Pregnancy complications and maternal cardiovascular risk: opportunities for intervention and screening? BMJ. 2002;325(7356):157-160.
312. Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ. 2005;330(7491):565-572.
313. Clark P, Walker ID, Govan L, Wu O, Greer IA. The GOAL study: a prospective examination of the impact of factor V Leiden and ABO(H) blood groups on haemorrhagic and thrombotic pregnancy outcomes. Br J Haematol. 2008;140(2):236-240.
314. Duley L, Henderson-Smart DJ, Meher S, King JF. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev. 2007;(2):CD004659.
315. Antithrombotic Trialists' (ATT) Collaboration; Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative metaanalysis of individual participant data from randomised trials. Lancet. 2009;373 (9678):1849-1860.
316. Greer IA. Pre-eclampsia matters. BMJ. 2005;330(7491):549-550.
317. Kaaja R. Predictors and risk factors of pre-eclampsia. Minerva Ginecol. 2008;60(5):421-429.
318. Hills FA, Abrahams VM, González-Timón B, et al. Heparin prevents programmed cell death in human trophoblast. Mol Hum Reprod. 2006;12(4):237-243.
319. Kalk JJ, Huisjes AJ, de Groot CJ, et al. Recurrence rate of pre-eclampsia in women with thrombophilia influenced by low-molecular-weight heparin treatment? Neth J Med.2004;62(3):83-87.
320. Mello G, Parretti E, Fatini C, et al. Low-molecular-weight heparin lowers the recurrence rate of preeclampsia and restores the physiological vascular changes in angiotensin-converting enzyme DD women. Hypertension. 2005;45(1):86-91.
321. Rey E, Garneau P, David M, et al. Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial. J Thromb Haemost. 2009;7(1):58-64.
322. Dao V, Rodger M. Anticoagulants to prevent placenta-mediated pregnancy complications: a review of current evidence. Curr Opin Hematol. 2009; 16(5):386-390.
323. Bassler D, Briel M, Montori VM, et al; STOPIT-2 Study Group. Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and metaregression analysis. JAMA. 2010;303(12):1180-1187.
324. Kaandorp S, Di Nisio M, Goddijn M, Middeldorp S. Aspirin or anticoagulants for treating recurrent miscarriage in women without antiphospholipid syndrome. Cochrane Database Syst Rev. 2009;(1):CD004734.
325. Dolitzky M, Inbal A, Segal Y, Weiss A, Brenner B, Carp H. A randomized study of thromboprophylaxis in women with unexplained consecutive recurrent miscarriages. Fertil Steril. 2006; 86(2):362- 366.
326. Mantha S, Bauer KA, Zwicker JI. Low molecular weight heparin to achieve live birth following unexplained pregnancy loss: a systematic review. J Thromb Haemost. 2010;8(2):263-268.
327. Kaandorp SP, Goddijn M, van der Post JAM, et al. Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. N Engl J Med. 2010;362(17):1586-1596.
328. Clark P, Walker ID, Langhorne P, et al Scottish Pregnancy Intervention Study (SPIN) Collaborators. SPIN (Scottish Pregnancy Intervention) study: a multicentre randomised controlled trial of low-molecular-weight heparin and low-dose aspirin in women with recurrent miscarriage. Blood. 2010;115(21):4162-4167.
329. Badawy AM, Khiary M, Sherif LS, Hassan M, Ragab A, Abdelall I. Low-molecular weight heparin in patients with recurrent early miscarriages of unknown aetiology. J Obstet Gynaecol. 2008;28(3):280-284.
330. Fawzy M, Shokeir T, El-Tatongy M, Warda O, El-Refaiey A-A, Mosbah A. Treatment options and pregnancy outcome in women with idiopathic recurrent miscarriage: a randomized placebo-controlled study. Arch Gynecol Obstet. 2008;278(1):33-38.
331. Whitlock RP, Sun JC, Fremes SE, Rubens FD, Teoh KH. Anti-thrombotic and thrombolytic therapy for valvular dis ease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2)(suppl):e576S- e600S.
332. James AH, Brancazio LR, Gehrig TR, Wang A, Ortel TL. Low-molecular-weight heparin for thromboprophylaxis in pregnant women with mechanical heart valves. J Matern Fetal Neonatal Med. 2006;19(9):543-549.
333. Oran B, Lee-Parritz A, Ansell J. Low molecular weight heparin for the prophylaxis of thromboembolism in women with prosthetic mechanical heart valves during pregnancy. Thromb Haemost. 2004;92(4):747-751.
334. Abildgaard U, Sandset PM, Hammerstrøm J, Gjestvang FT, Tveit A. Management of pregnant women with mechanical heart valve prosthesis: thromboprophylaxis with low molecular weight heparin. Thromb Res. 2009;124(3):262-267.
335. Quinn J, Von Klemperer K, Brooks R, Peebles D, Walker F, Cohen H. Use of high intensity adjusted dose low molecular weight heparin in women with mechanical heart valves during pregnancy: a single-center experience. Haematologica.2009;94(11):1608-1612.
336. Yinon Y, Siu SC, Warshafsky C, et al. Use of low molecular weight heparin in pregnant women with mechanical heart valves. Am J Cardiol.
337. Kawamata K, Neki R, Yamanaka K, et al. Risks and pregnancy outcome in women with prosthetic mechanical heart valve replacement. Circ J. 2007;71(2):211-213.
338. Khamooshi AJ, KashfiF, Hoseini S, Tabatabaei MB, Javadpour H, Noohi F. Anticoagulation for prosthetic heart valves in pregnancy. Is there an answer? Asian Cardiovasc Thorac Ann. 2007;15(6):493-496.
339. Lee JH, Park NH, Keum DY, Choi SY, Kwon KY, Cho CH. Low molecular weight heparin treatment in pregnant women with a mechanical heart valve prosthesis. J Korean Med Sci.2007;22(2):258-261.
340. McLintock C, McCowan LME, North RA. Maternal complications and pregnancy outcome in women with mechanical prosthetic heart valves treated with enoxaparin. BJOG.2009;116(12):1585-1592.
341. Injection L.(package insert) . Bridgewater, NJ: Aventis Pharmaceuticals; 2004.
342. Turpie AGG, Gent M, Laupacis A, et al. A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. N Engl J Med. 1993;329(8):524-529.
343. Macklin R. Enrolling pregnant women in biomedical research. Lancet. 2010;375(9715):632-633.